Controlled Release Delivery Conference 2018

SMi Group21 - 22 March, London, UK.
An industry-leading show, SMi have been running this conference for 15 years - a testament of how vital this particular focus is to the biotech and pharma sector. As physicians and scientists continue to find strategies to assist in simplifying treatment schedules for patients, a pharma focus continues to move towards innovative controlled release technologies to improve drug transport to target.

Moreover, with the global oral controlled release drug delivery technology market expected to expand at 7.2% CAGR between 2017-2027 (with an estimated revenue of US$50B by 2027), now is the time to get ahead of the game by exploring and understanding innovations in drug delivery, nanoparticles/nanomedicine & QbD, CNS drug delivery and therapeutic application.

Who will be speaking?

  • Howard Stevens, Emeritus Professor, University of Strathclyde (CHAIRMAN)
  • Joël Richard, Senior Vice President, Peptides Development, Ipsen (CHAIRMAN)
  • Mohamed Albed Alhnan, Senior Lecturer, University of Central Lancashire
  • Pavel Farkas, Senior Director - Biopharmaceutics/ Clinical Development, PLIVA
  • Barry Friend, Sr. Technical Manager, Colorcon
  • Sebastian Schwier, Project Director / Int. Technical Project Leader, ‎Grünenthal
  • Karsten Lindhardt, CSO, Head R&D, Egalet
  • Teofilo Vasconcelos, Formulation Manager, Bial
  • Guillaume Saint-Pierre, Chief Executive Officer and Cofounder, PeptiGelDesign

Highlights this March 2018

  • Understand the impact of the current EU Guideline on clinical evaluation of modified release drugs from a pharmaceutical perspective, with a talk from PLIVA
  • Discover new technologies and innovations for the development of Controlled Release drugs including Lipid-composite microparticles, Molecular Envelope Technology (MET) nanoparticles and Abuse-Deterrent Formulations
  • Focus on Successful Oral Technologies progressing in the clinic, with talks discussing lessons learned from clinical studies
  • Learn about the advances and challenges in Paediatric controlled release formulations, including taste-masking and oral formulation challenges
  • ...and more.

For further information and to register, please visit:
https://www.smi-online.co.uk/pharmaceuticals/uk/controlled-release

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...